MEDIUM confidence: 100% data completeness, but the composite (48) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
The QScore of 48 for Alnylam Pharmaceuticals indicates a neutral outlook, driven by a high growth score of 76, reflecting strong revenue and earnings growth, with EPS growth at 209.6%. However, this is offset by a low value score of 24, due to the stock trading at a premium with a P/E of 66.9. The company exhibits strong profitability, with an ROE near 98%, but momentum is weak, with a 12-month return of -9.4% and a bearish moving average trend.
Net insider -$7.4M over 180 days (0 open-market buys, 73 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $409 (last qtr, 2 analysts) → $0 (last mo, 0) (-100.0%).
Buy-rated share 72% → 73% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Apr 2026 | $0.87 | $1.51 | +73.2% |
| Feb 2026 | $1.16 | $0.82 | -29.3% |
| Oct 2025 | $0.56 | $2.90 | +416.9% |
| Jul 2025 | $-0.54 | $0.32 | +158.9% |
| May 2025 | $-0.89 | $-0.01 | +98.9% |
| Feb 2025 | $-0.62 | $0.06 | +109.7% |
| Oct 2024 | $-0.92 | $-0.50 | +45.5% |
| Aug 2024 | $-1.07 | $0.56 | +152.3% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $844M— | $1.0B+22.9% | $1.8B+76.2% | $2.2B+23.0% | $3.7B+65.2% |
| EPS (dil.) | $-7.20— | $-9.30n/m | $-3.52n/m | $-2.18n/m | $2.33n/m |
| Free Cash Flow | -$718M— | -$613Mn/m | $42Mn/m | -$43M-201.5% | $465Mn/m |
| Gross Margin | 83.4% | 83.7%+0.3pp | 83.0%-0.7pp | 85.6%+2.6pp | 81.8%-3.8pp |
| Operating Margin | -83.9% | -75.7%+8.3pp | -15.4%+60.2pp | -7.9%+7.6pp | 13.5%+21.4pp |
| Net Margin | -101.0% | -109.0%-8.0pp | -24.1%+85.0pp | -12.4%+11.7pp | 8.4%+20.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.